Financial Contrast: Hero Technologies (OTCMKTS:HENC) vs. GE HealthCare Technologies (NASDAQ:GEHC)

Hero Technologies (OTCMKTS:HENC) and GE HealthCare Technologies (NASDAQ:GEHC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Hero Technologies and GE HealthCare Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hero Technologies	N/A	N/A	N/A
GE HealthCare Technologies	11.22%	23.93%	6.29%

Volatility & Risk

Hero Technologies has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Earnings and Valuation

This table compares Hero Technologies and GE HealthCare Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hero Technologies	N/A	N/A	-$540,000.00	N/A	N/A
GE HealthCare Technologies	$19.67 billion	1.80	$1.99 billion	$4.88	15.86

GE HealthCare Technologies has higher revenue and earnings than Hero Technologies.

Analyst Recommendations

This is a breakdown of current ratings for Hero Technologies and GE HealthCare Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hero Technologies	0	0	0	0	0.00
GE HealthCare Technologies	0	6	6	0	2.50

GE HealthCare Technologies has a consensus target price of $85.00, indicating a potential upside of 9.85%. Given GE HealthCare Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Hero Technologies.

Institutional and Insider Ownership

82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.2% of Hero Technologies shares are held by insiders. Comparatively, 0.3% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

GE HealthCare Technologies beats Hero Technologies on 10 of the 11 factors compared between the two stocks.

About Hero Technologies

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.